Legal & General Group
JANX icon

Legal & General Group’s Janux Therapeutics JANX Stock Holding History

Legal & General Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Sell
30,998
-2,381
-7% -$34.5K ﹤0.01% 2413
2026
Q1 		$464K Sell
33,379
-10,088
-23% -$138K ﹤0.01% 2370
2025
Q4 		$600K Buy
43,467
+5,551
+15% +$131K ﹤0.01% 2366
2025
Q3 		$927K Sell
37,916
-9,437
-20% -$230K ﹤0.01% 2261
2025
Q2 		$1.09M Buy
47,353
+5,055
+12% +$133K ﹤0.01% 2208
2025
Q1 		$1.14M Buy
42,298
+7,758
+22% +$292K ﹤0.01% 2141
2024
Q4 		$1.85M Buy
34,540
+12,509
+57% +$662K ﹤0.01% 2004
2024
Q3 		$1M Buy
22,031
+746
+4% +$32.5K ﹤0.01% 2236
2024
Q2 		$892K Buy
21,285
+5,178
+32% +$243K ﹤0.01% 2236
2024
Q1 		$606K Buy
16,107
+6,226
+63% +$136K ﹤0.01% 2351
2023
Q4 		$106K Hold
9,881
– – ﹤0.01% 2760
2023
Q3 		$99.6K Sell
9,881
-313
-3% -$3.61K ﹤0.01% 2829
2023
Q2 		$121K Buy
10,194
+5,484
+116% +$73.3K ﹤0.01% 2816
2023
Q1 		$57K Buy
4,710
+2,968
+170% +$49.4K ﹤0.01% 2854
2022
Q4 		$22.8K Hold
1,742
– – ﹤0.01% 3124
2022
Q3 		$24K Buy
1,742
+302
+21% +$4.04K ﹤0.01% 3161
2022
Q2 		$18K Sell
1,440
-260
-15% -$3.08K ﹤0.01% 3272
2022
Q1 		$24K Buy
1,700
+461
+37% +$7.54K ﹤0.01% 3190
2021
Q4 		$24K Hold
1,239
– – ﹤0.01% 3212
2021
Q3 		$27K Buy
+1,239
New +$35.6K ﹤0.01% 3166

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group's JANX Position: Q2 2026 in Review

Legal & General Group reduced its Janux Therapeutics (JANX) stake by 7.1% in Q2 2026, selling an estimated $34.5K and leaving 30,998 shares worth $476K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

Legal & General Group first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.85M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Legal & General Group held 30,998 shares of Janux Therapeutics worth $476K as of Q2 2026.
  • Legal & General Group sold 2,381 Janux Therapeutics shares in Q2 2026, an estimated $34.5K.
  • Janux Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2413 holding.
  • Legal & General Group first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Legal & General Group's Janux Therapeutics position peaked at $1.85M in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.